Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release methylphenidate to reduce cannabis use in young cannabis-dependent patients with ADHD
2017-000386-77Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of methylphenidate in cannabis use disorder (CUD) and attention deficit hyperactivity disorder (ADHD), sponsored by Assistance publique - Hôpitaux de Paris. Started Jan 2018; status: terminated.
02
Drugs
methylphenidate
03
Conditions
cannabis use disorder (CUD)attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2017-000386-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000386-77.